<?xml version='1.0' encoding='utf-8'?>
<document id="28770300"><sentence text="Phase I study of veliparib in combination with gemcitabine."><entity charOffset="17-26" id="DDI-PubMed.28770300.s1.e0" text="veliparib" /><entity charOffset="47-58" id="DDI-PubMed.28770300.s1.e1" text="gemcitabine" /><pair ddi="false" e1="DDI-PubMed.28770300.s1.e0" e2="DDI-PubMed.28770300.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28770300.s1.e0" e2="DDI-PubMed.28770300.s1.e1" /></sentence><sentence text="Veliparib (ABT-888) is an oral PARP inhibitor expected to increase gemcitabine activity"><entity charOffset="0-9" id="DDI-PubMed.28770300.s2.e0" text="Veliparib" /><entity charOffset="11-18" id="DDI-PubMed.28770300.s2.e1" text="ABT-888" /><entity charOffset="67-78" id="DDI-PubMed.28770300.s2.e2" text="gemcitabine" /><pair ddi="false" e1="DDI-PubMed.28770300.s2.e0" e2="DDI-PubMed.28770300.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28770300.s2.e0" e2="DDI-PubMed.28770300.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28770300.s2.e0" e2="DDI-PubMed.28770300.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28770300.s2.e1" e2="DDI-PubMed.28770300.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28770300.s2.e1" e2="DDI-PubMed.28770300.s2.e2" /></sentence><sentence text=" This phase I determined the maximal tolerable dose (MTD), dose-limiting toxicities (DLT), antitumor activity, pharmacokinetics (PK), and pharmacodynamics (PD) of veliparib combined with gemcitabine"><entity charOffset="163-172" id="DDI-PubMed.28770300.s3.e0" text="veliparib" /><entity charOffset="187-198" id="DDI-PubMed.28770300.s3.e1" text="gemcitabine" /><pair ddi="false" e1="DDI-PubMed.28770300.s3.e0" e2="DDI-PubMed.28770300.s3.e0" /><pair ddi="false" e1="DDI-PubMed.28770300.s3.e0" e2="DDI-PubMed.28770300.s3.e1" /></sentence><sentence text="" /><sentence text="Patients with advanced solid tumors received veliparib (10-40-mg PO BID) on chemotherapy weeks with gemcitabine 500-750-mg/m2 IV on days 1, 8, and 15 (28-day cycle), or on days 1 and 8 (21-day cycle)"><entity charOffset="45-54" id="DDI-PubMed.28770300.s5.e0" text="veliparib" /><entity charOffset="100-111" id="DDI-PubMed.28770300.s5.e1" text="gemcitabine" /><pair ddi="false" e1="DDI-PubMed.28770300.s5.e0" e2="DDI-PubMed.28770300.s5.e0" /><pair ddi="false" e1="DDI-PubMed.28770300.s5.e0" e2="DDI-PubMed.28770300.s5.e1" /></sentence><sentence text=" The MTD, DLT, adverse events, PK, and PD were evaluated" /><sentence text="" /><sentence text="Eleven patients were enrolled on the 28-day schedule" /><sentence text=" The 28-day schedule was considered intolerable and amended to a 21-day schedule, with 20 patients enrolled" /><sentence text=" Grade ≥ 3 adverse events were myelosuppression-related" /><sentence text=" The MTD was determined to be 750-mg/m2 gemcitabine IV on days 1 and 8- and 20-mg PO veliparib BID days 1-14 on a 21-day schedule" /><sentence text=" Of 27 patients evaluable for response, 3 had PR and 15 had SD" /><sentence text=" There was no evidence of any major drug-drug interaction, and PK parameter values for veliparib, gemcitabine, and dFdU were as expected"><entity charOffset="87-96" id="DDI-PubMed.28770300.s13.e0" text="veliparib" /><entity charOffset="98-109" id="DDI-PubMed.28770300.s13.e1" text="gemcitabine" /><entity charOffset="115-119" id="DDI-PubMed.28770300.s13.e2" text="dFdU" /><pair ddi="false" e1="DDI-PubMed.28770300.s13.e0" e2="DDI-PubMed.28770300.s13.e0" /><pair ddi="false" e1="DDI-PubMed.28770300.s13.e0" e2="DDI-PubMed.28770300.s13.e1" /><pair ddi="false" e1="DDI-PubMed.28770300.s13.e0" e2="DDI-PubMed.28770300.s13.e2" /><pair ddi="false" e1="DDI-PubMed.28770300.s13.e1" e2="DDI-PubMed.28770300.s13.e1" /><pair ddi="false" e1="DDI-PubMed.28770300.s13.e1" e2="DDI-PubMed.28770300.s13.e2" /></sentence><sentence text=" Analysis of PBMCs showed evidence of PARP inhibition and DNA damage associated with therapy" /><sentence text="" /><sentence text="Gemcitabine at 750-mg/m2 IV on days 1 and 8 combined with veliparib at a dose of 20-mg PO BID days 1-14 on a 21-day schedule is relatively well-tolerated, with manageable, expected toxicities"><entity charOffset="0-11" id="DDI-PubMed.28770300.s16.e0" text="Gemcitabine" /><entity charOffset="58-67" id="DDI-PubMed.28770300.s16.e1" text="veliparib" /><pair ddi="false" e1="DDI-PubMed.28770300.s16.e0" e2="DDI-PubMed.28770300.s16.e0" /><pair ddi="false" e1="DDI-PubMed.28770300.s16.e0" e2="DDI-PubMed.28770300.s16.e1" /></sentence><sentence text=" Clinical responses were observed in a pretreated population of patients, suggesting that this combination should be further evaluated in the phase II setting" /><sentence text="" /></document>